Yatin Suneja analyst GUGGENHEIM

Currently out of the existing stock ratings of Yatin Suneja, 173 are a BUY (85.22%), 30 are a HOLD (14.78%).

Yatin Suneja

Work Performance Price Targets & Ratings Chart

Analyst Yatin Suneja, currently employed at GUGGENHEIM, carries an average stock price target met ratio of 48.59% that have a potential upside of 51.46% achieved within 284 days.

Yatin Suneja’s has documented 443 price targets and ratings displayed on 47 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on PRAX, Praxis Precision Medicines  at 16-Oct-2025.

Wall Street Analyst Yatin Suneja

Analyst best performing recommendations are on IMVT (IMMUNOVANT ).
The best stock recommendation documented was for IMVT (IMMUNOVANT ) at 9/22/2023. The price target of $32 was fulfilled within 4 days with a profit of $11.61 (56.94%) receiving and performance score of 142.35.

Average potential price target upside

ACAD ACADIA Pharmaceuticals ALXN Alexion Pharmaceuticals ARGX argenx NV ADR BIIB Biogen BTAI BioXcel Therapeutics CELG Celgene GBT Global Blood Therapeutics GWPH GW Pharmaceuticals plc IFRX InflaRx N.V. LJPC La Jolla Pharmaceutical Co ORPH Orphazyme A/S PHAT Phathom Pharmaceuticals SAGE Sage Therapeutic XENE Xenon Pharmaceuticals ZGNX Zogenix REGN Regeneron Pharmaceuticals SGEN Seagen AGIO Agios Pharm ANAB AnaptysBio ELYM Eliem Therapeutics AXSM Axsome Therapeutics CLDX Celldex Therapeutics EYPT Eyepoint Pharmaceuticals SRZN Surrozen BLCO Bausch + Lomb Corp HZNP Horizon Pharma PLC RXDX Prometheus Biosciences KRTX Karuna Therapeutics IMVT Immunovant  LBPH Longboard Pharmaceuticals LRMR Larimar Therapeutics RAPT RAPT Therapeutics RLMD Relmada Therapeutics VIGL Vigil Neuroscience VRNA Verona Pharma PLC ADR CABA Cabaletta Bio MLTX MoonLake Immunotherapeutics RETA Reata Pharmaceuticals ROIV Roivant Sciences Ltd SEEL Seelos Therapeutics NBIX Neurocrine Biosciences PRAX Praxis Precision Medicines  TRML Tourmaline Bio ARNA Arena Pharmaceuticals ACET Adicet Bio PRNB Principia Biopharma TGTX TG Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy

$33

$10.98 (49.86%)

$34

29 days ago
(28-Sep-2025)

8/13 (61.54%)

$11.68 (54.78%)

113

Buy

$28

$5.98 (27.16%)

$30

1 months 4 days ago
(23-Sep-2025)

0/10 (0%)

$6.74 (31.70%)

Buy

$39

$16.98 (77.11%)

$35

1 months 17 days ago
(10-Sep-2025)

7/12 (58.33%)

$14.8 (61.16%)

671

Buy

$39

$16.98 (77.11%)

$32

1 months 19 days ago
(08-Sep-2025)

1/5 (20%)

$14.16 (57.00%)

349

Hold

$24

$1.98 (8.99%)

$23

2 months 21 days ago
(06-Aug-2025)

10/13 (76.92%)

$-0.4 (-1.64%)

157

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Yatin Suneja is most bullish on?

Potential upside of $252.68 has been obtained for ARGX (ARGENX NV ADR)

Which stock is Yatin Suneja is most reserved on?

Potential downside of -$0 has been obtained for LRMR (LARIMAR THERAPEUTICS)

What Year was the first public recommendation made by Yatin Suneja?

On 2016

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?